
AI is about to change healthcare. These 8 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To stay invested in Metaplanet after a half‑year loss of ¥182.77 billion, you have to believe that its business model and capital strategy can justify persistent dilution, volatility and ongoing losses. The investment case has centered on fast revenue growth, access to capital and a willingness to reinvent the balance sheet, even as the company remains unprofitable and trades on a very rich price‑to‑sales multiple. The August results and the swing from profit to a very large loss sharpen near‑term focus on balance‑sheet resilience and the quality of earnings, rather than growth forecasts. The board’s move to revisit stock acquisition rights, implement lock‑ups and tweak long‑term incentives fits directly into this, hinting at tighter alignment but also underscoring how dependent the story is on equity issuance and governance decisions.
However, investors should also recognise how heavily this story now leans on fresh capital and governance execution. Metaplanet's shares are on the way up, but they could be overextended by 18%. Uncover the fair value now.Explore 3 other fair value estimates on Metaplanet - why the stock might be worth less than half the current price!
Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
Our daily scans reveal stocks with breakout potential. Don't miss this chance:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com